IRVINE, Calif., Nov. 11, 2016 /PRNewswire/ -- Syneron
Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device
company, announced today that Hugo
Goldman, Chief Financial Officer, is scheduled to
participate in the Canaccord Genuity Medical Technologies and
Diagnostics Forum on November 17,
2016 in New York City. The
conference will allow institutional investors to meet with Mr.
Goldman and will include a fireside chat presentation.
Conference:
|
Canaccord Genuity
Medical Technologies and Diagnostics Forum
|
Date:
|
Thursday, November
17, 2016
|
Time:
|
8:30 am ET
|
The fireside chat presentation will be webcast live over the
Internet and can be accessed through the Investor Relations section
on Syneron's website at www.investors.syneron.com. Please go
to the website a few minutes early, as it may be necessary to
download audio software to hear the presentations.
About Syneron Candela:
Syneron Candela is a
leading global aesthetic device company with a comprehensive
product portfolio and a global distribution footprint. The
Company's technology enables physicians to provide advanced
solutions for a broad range of medical-aesthetic applications
including body contouring, hair removal, wrinkle reduction, tattoo
removal, women's intimate wellness treatments, improving the skin's
appearance through the treatment of superficial benign vascular and
pigmented lesions, and the treatment of acne, leg veins and
cellulite. The Company has a wide portfolio of trusted, leading
products including UltraShape, VelaShape, GentleLase, VBeam
Perfecta, PicoWay, CO2RE, CO2RE Intima, Profound and elōs Plus.
Founded in 2000, the company markets, services and supports its
products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide.
For additional information, please visit
http://www.syneron-candela.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/syneron-medical-to-participate-in-the-canaccord-genuity-medical-technologies-and-diagnostics-forum-300361565.html
SOURCE Syneron Medical Ltd.